Results 11 to 20 of about 5,544 (172)
Urate lowering therapy in primary care: rheum for improvement [PDF]
Exploration of Musculoskeletal DiseasesPrimary care physicians (PCPs) play a critical role in the management of gout worldwide. However, significant gaps in gout care persist, underscoring the need for improved approaches to its management.
Emilie Schurenberg +2 more
doaj +2 more sources
Frontiers in Pharmacology, 2022 Dysfunctional missense variant of organic anion transporter 10 (OAT10/SLC22A13), rs117371763 (c.1129C>T; p.R377C), is associated with a lower susceptibility to gout.
Yu Toyoda +15 more
doaj +1 more source
The many faces of gout: modern treatment concepts
Клинический разбор в общей медицине, 2021 Gout is a systemic disease caused by the deposition of monosodium urate crystals in various tissues and organs with the subsequent development of autoinflammation.
Irina N. Bobkova, Elena S. Kamyshova
doaj +1 more source
Urate-lowering drugs in the treatment of gout: The unknown about the known
Научно-практическая ревматология, 2021 The main direction of drug therapy for gout and other diseases associated with hyperuricemia is the long-term use of drugs aimed at correcting the level of uric acid.
T. S. Panevin +2 more
doaj +1 more source
Adherence with urate-lowering therapies for the treatment of gout [PDF]
Arthritis Research & Therapy, 2009 Abstract Introduction Adherence to urate-lowering drugs (ULDs) has not been well evaluated among those with gout. Our aim was to assess the level and determinants of non-adherence with ULDs prescribed for gout.
Harrold, Leslie R +6 more
openaire +3 more sources
Estradiol regulates intestinal ABCG2 to promote urate excretion via the PI3K/Akt pathway
Nutrition & Metabolism, 2021 Objectives The study of sex differences in hyperuricemia can provide not only a theoretical basis for this clinical phenomenon but also new therapeutic targets for urate-lowering therapy.
Lei Liu +5 more
doaj +1 more source
Factors associated with initiation and persistence of urate-lowering therapy [PDF]
Arthritis Research & Therapy, 2017 Gout is the most common inflammatory arthritic disease and is caused by crystal deposition secondary to persistent hyperuricemia. Etiological treatment with urate-lowering therapy (ULT) has been available since the 1950s but previous studies have demonstrated suboptimal degree of treatment.
Mats Dehlin +5 more
openaire +2 more sources
Cardiac and renal protective effects of urate-lowering therapy [PDF]
Rheumatology, 2017 Patients with gout often have co-morbidities such as cardiovascular disease, renal failure and metabolic syndrome components. Some studies, but not all, have suggested that hyperuricaemia and gout are associated with increased risk of myocardial infarction, renal failure and death primarily because of increased risk of cardiovascular events. Therefore,
Pascal, Richette +2 more
openaire +2 more sources
Contentious Issues in Gout Management: The Story so Far
Open Access Rheumatology: Research and Reviews, 2021 Mohamed Talaat,1 Kyle Park,1 Naomi Schlesinger2 1Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ, USA; 2Division of Rheumatology, Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, 08903-0019 ...
Talaat M, Park K, Schlesinger N
doaj
Bariatric surgery as urate-lowering therapy in severe obesity [PDF]
Annals of the Rheumatic Diseases, 2014 Gout represents a metabolically driven inflammatory arthropathy, which could be substantially influenced by adiposity and lifestyle risk factors. As such, influenced by the trends in lifestyle factors associated with Westernisation,1 ,2 gout prevalence has increased in the last few decades worldwide (eg, 3.9% of US adults (8.3 million) in 2007–20083).4
Hyon K, Choi, Yuqing, Zhang
openaire +2 more sources